Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918

J Med Virol. 2021 May;93(5):2626-2627. doi: 10.1002/jmv.26879. Epub 2021 Mar 1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19*
  • Critical Illness
  • Erythropoietin*
  • Humans
  • Recombinant Proteins
  • SARS-CoV-2

Substances

  • Recombinant Proteins
  • Erythropoietin

Grants and funding